A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)
The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. This study evaluated the effects of intratumoral ONYX-015 injection combined with systemic chemotherapy. Inclu...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2000-09, Vol.7 (8), p.588-592 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 592 |
|---|---|
| container_issue | 8 |
| container_start_page | 588 |
| container_title | Annals of surgical oncology |
| container_volume | 7 |
| creator | Lamont, J P Nemunaitis, J Kuhn, J A Landers, S A McCarty, T M |
| description | The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. This study evaluated the effects of intratumoral ONYX-015 injection combined with systemic chemotherapy.
Inclusion criteria included: (1) recurrent squamous cell carcinoma of the head and neck, not surgically salvageable, (2) target tumor amenable to direct injection, and (3) no prior chemotherapy for recurrent disease. Patients received ONYX-015 (10(10) plaque-forming units) intratumorally for 5 days, cisplatin (80 mg/m2) on day 1, and 5-fluorouracil (800-1000 mg/m2) on days 1-5. This cycle was repeated every 3 weeks. Serial physical examination and computed tomography were used to assess tumor size and treatment response.
Fourteen patients were enrolled, and nine patients were evaluable for response at the time of enrollment. The mean age of the evaluable patients was 60.8 years (range, 46-71 years). Mean maximum tumor diameter was 4.8 cm (range, 1.9-10.5 cm). Treatment-related toxicity included nausea (n = 7, 77.8%), vomiting (n = 5, 55.6%), mucositis (n = 5, 55.6%), pain at the injection site (n = 5, 55.6%), constipation (n = 4, 44.4%), and fatigue (n = 4, 44.4%). Locoregional tumor control was obtained in all nine patients (100%) (mean observation time, 157 days). Complete clinical response was seen in three patients (33.3%), partial response was seen in three patients (33.3%), minor response was seen in one patient (11.1%), and two patients (22.2%) had stable disease. Median time to local progression of disease has not been reached (range, 35-356 days).
ONYX-015 adenovirus plus systemic cisplatin and 5-fluorouracil provides antitumor activity and local tumor control in patients with recurrent squamous cell carcinoma of the head and neck. This novel treatment approach offers hope for patients with limited treatment alternatives and provides the foundation for a phase III clinical trial. |
| doi_str_mv | 10.1007/BF02725338 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19606723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1571790581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c273t-5ef087f1e92a73e20e08c91bd7f652c32a5ade662c519a094f1593a45f96bad53</originalsourceid><addsrcrecordid>eNpdkd1q3DAQhUVoaX7amzxAEb0oScGNfizJuswuSbuwJDcJJFdmVh6zTm3Zkeyl-yJ93mqThUCuZhi-OZyZQ8gpZz85Y-Zids2EEUrK4oAccSXzLNcF_5B6povMCq0OyXGMT4xxI5n6RA552lNKmSPy75IOoY8DurHZIB3WEJEuFnQMDbS0r-ntzeNDxriiUKHvN02YIgVfUbfGrh_XGGDY0sbTgG4KAf1I4_MEXZ8wh21LHQTX-L6DnVji6RqhelHw6P7Qs91oBtu2DxT_Dhga9A7PP5OPNbQRv-zrCbm_vrqb_86Wt78W88tl5oSRY6awZoWpOVoBRqJgyApn-aoytVbCSQEq2dZaOMUtMJvXXFkJuaqtXkGl5An5_qqbnvA8YRzLrok73-AxnVByq5k2Qibw2zvwqZ-CT95Kkazk3OYsQT9eIZdeGgPW5RCaDsK25KzcRVW-RZXgr3vFadVh9Ybus5H_AdBgjew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227341940</pqid></control><display><type>article</type><title>A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Lamont, J P ; Nemunaitis, J ; Kuhn, J A ; Landers, S A ; McCarty, T M</creator><creatorcontrib>Lamont, J P ; Nemunaitis, J ; Kuhn, J A ; Landers, S A ; McCarty, T M</creatorcontrib><description>The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. This study evaluated the effects of intratumoral ONYX-015 injection combined with systemic chemotherapy.
Inclusion criteria included: (1) recurrent squamous cell carcinoma of the head and neck, not surgically salvageable, (2) target tumor amenable to direct injection, and (3) no prior chemotherapy for recurrent disease. Patients received ONYX-015 (10(10) plaque-forming units) intratumorally for 5 days, cisplatin (80 mg/m2) on day 1, and 5-fluorouracil (800-1000 mg/m2) on days 1-5. This cycle was repeated every 3 weeks. Serial physical examination and computed tomography were used to assess tumor size and treatment response.
Fourteen patients were enrolled, and nine patients were evaluable for response at the time of enrollment. The mean age of the evaluable patients was 60.8 years (range, 46-71 years). Mean maximum tumor diameter was 4.8 cm (range, 1.9-10.5 cm). Treatment-related toxicity included nausea (n = 7, 77.8%), vomiting (n = 5, 55.6%), mucositis (n = 5, 55.6%), pain at the injection site (n = 5, 55.6%), constipation (n = 4, 44.4%), and fatigue (n = 4, 44.4%). Locoregional tumor control was obtained in all nine patients (100%) (mean observation time, 157 days). Complete clinical response was seen in three patients (33.3%), partial response was seen in three patients (33.3%), minor response was seen in one patient (11.1%), and two patients (22.2%) had stable disease. Median time to local progression of disease has not been reached (range, 35-356 days).
ONYX-015 adenovirus plus systemic cisplatin and 5-fluorouracil provides antitumor activity and local tumor control in patients with recurrent squamous cell carcinoma of the head and neck. This novel treatment approach offers hope for patients with limited treatment alternatives and provides the foundation for a phase III clinical trial.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1007/BF02725338</identifier><identifier>PMID: 11005557</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Adenovirus ; Adenoviruses, Human - genetics ; Aged ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - therapy ; Cisplatin - adverse effects ; Cisplatin - therapeutic use ; Disease Progression ; Female ; Fluorouracil - adverse effects ; Fluorouracil - therapeutic use ; Gene Deletion ; Genetic Therapy - methods ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - therapy ; Humans ; Injections ; Male ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - therapy ; Remission Induction</subject><ispartof>Annals of surgical oncology, 2000-09, Vol.7 (8), p.588-592</ispartof><rights>The Society of Surgical Oncology, Inc. 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c273t-5ef087f1e92a73e20e08c91bd7f652c32a5ade662c519a094f1593a45f96bad53</citedby><cites>FETCH-LOGICAL-c273t-5ef087f1e92a73e20e08c91bd7f652c32a5ade662c519a094f1593a45f96bad53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11005557$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamont, J P</creatorcontrib><creatorcontrib>Nemunaitis, J</creatorcontrib><creatorcontrib>Kuhn, J A</creatorcontrib><creatorcontrib>Landers, S A</creatorcontrib><creatorcontrib>McCarty, T M</creatorcontrib><title>A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. This study evaluated the effects of intratumoral ONYX-015 injection combined with systemic chemotherapy.
Inclusion criteria included: (1) recurrent squamous cell carcinoma of the head and neck, not surgically salvageable, (2) target tumor amenable to direct injection, and (3) no prior chemotherapy for recurrent disease. Patients received ONYX-015 (10(10) plaque-forming units) intratumorally for 5 days, cisplatin (80 mg/m2) on day 1, and 5-fluorouracil (800-1000 mg/m2) on days 1-5. This cycle was repeated every 3 weeks. Serial physical examination and computed tomography were used to assess tumor size and treatment response.
Fourteen patients were enrolled, and nine patients were evaluable for response at the time of enrollment. The mean age of the evaluable patients was 60.8 years (range, 46-71 years). Mean maximum tumor diameter was 4.8 cm (range, 1.9-10.5 cm). Treatment-related toxicity included nausea (n = 7, 77.8%), vomiting (n = 5, 55.6%), mucositis (n = 5, 55.6%), pain at the injection site (n = 5, 55.6%), constipation (n = 4, 44.4%), and fatigue (n = 4, 44.4%). Locoregional tumor control was obtained in all nine patients (100%) (mean observation time, 157 days). Complete clinical response was seen in three patients (33.3%), partial response was seen in three patients (33.3%), minor response was seen in one patient (11.1%), and two patients (22.2%) had stable disease. Median time to local progression of disease has not been reached (range, 35-356 days).
ONYX-015 adenovirus plus systemic cisplatin and 5-fluorouracil provides antitumor activity and local tumor control in patients with recurrent squamous cell carcinoma of the head and neck. This novel treatment approach offers hope for patients with limited treatment alternatives and provides the foundation for a phase III clinical trial.</description><subject>Adenovirus</subject><subject>Adenoviruses, Human - genetics</subject><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Cisplatin - adverse effects</subject><subject>Cisplatin - therapeutic use</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Fluorouracil - adverse effects</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gene Deletion</subject><subject>Genetic Therapy - methods</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Humans</subject><subject>Injections</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Remission Induction</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkd1q3DAQhUVoaX7amzxAEb0oScGNfizJuswuSbuwJDcJJFdmVh6zTm3Zkeyl-yJ93mqThUCuZhi-OZyZQ8gpZz85Y-Zids2EEUrK4oAccSXzLNcF_5B6povMCq0OyXGMT4xxI5n6RA552lNKmSPy75IOoY8DurHZIB3WEJEuFnQMDbS0r-ntzeNDxriiUKHvN02YIgVfUbfGrh_XGGDY0sbTgG4KAf1I4_MEXZ8wh21LHQTX-L6DnVji6RqhelHw6P7Qs91oBtu2DxT_Dhga9A7PP5OPNbQRv-zrCbm_vrqb_86Wt78W88tl5oSRY6awZoWpOVoBRqJgyApn-aoytVbCSQEq2dZaOMUtMJvXXFkJuaqtXkGl5An5_qqbnvA8YRzLrok73-AxnVByq5k2Qibw2zvwqZ-CT95Kkazk3OYsQT9eIZdeGgPW5RCaDsK25KzcRVW-RZXgr3vFadVh9Ybus5H_AdBgjew</recordid><startdate>200009</startdate><enddate>200009</enddate><creator>Lamont, J P</creator><creator>Nemunaitis, J</creator><creator>Kuhn, J A</creator><creator>Landers, S A</creator><creator>McCarty, T M</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope></search><sort><creationdate>200009</creationdate><title>A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)</title><author>Lamont, J P ; Nemunaitis, J ; Kuhn, J A ; Landers, S A ; McCarty, T M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c273t-5ef087f1e92a73e20e08c91bd7f652c32a5ade662c519a094f1593a45f96bad53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adenovirus</topic><topic>Adenoviruses, Human - genetics</topic><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Cisplatin - adverse effects</topic><topic>Cisplatin - therapeutic use</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Fluorouracil - adverse effects</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gene Deletion</topic><topic>Genetic Therapy - methods</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Humans</topic><topic>Injections</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Remission Induction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamont, J P</creatorcontrib><creatorcontrib>Nemunaitis, J</creatorcontrib><creatorcontrib>Kuhn, J A</creatorcontrib><creatorcontrib>Landers, S A</creatorcontrib><creatorcontrib>McCarty, T M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamont, J P</au><au>Nemunaitis, J</au><au>Kuhn, J A</au><au>Landers, S A</au><au>McCarty, T M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)</atitle><jtitle>Annals of surgical oncology</jtitle><addtitle>Ann Surg Oncol</addtitle><date>2000-09</date><risdate>2000</risdate><volume>7</volume><issue>8</issue><spage>588</spage><epage>592</epage><pages>588-592</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. This study evaluated the effects of intratumoral ONYX-015 injection combined with systemic chemotherapy.
Inclusion criteria included: (1) recurrent squamous cell carcinoma of the head and neck, not surgically salvageable, (2) target tumor amenable to direct injection, and (3) no prior chemotherapy for recurrent disease. Patients received ONYX-015 (10(10) plaque-forming units) intratumorally for 5 days, cisplatin (80 mg/m2) on day 1, and 5-fluorouracil (800-1000 mg/m2) on days 1-5. This cycle was repeated every 3 weeks. Serial physical examination and computed tomography were used to assess tumor size and treatment response.
Fourteen patients were enrolled, and nine patients were evaluable for response at the time of enrollment. The mean age of the evaluable patients was 60.8 years (range, 46-71 years). Mean maximum tumor diameter was 4.8 cm (range, 1.9-10.5 cm). Treatment-related toxicity included nausea (n = 7, 77.8%), vomiting (n = 5, 55.6%), mucositis (n = 5, 55.6%), pain at the injection site (n = 5, 55.6%), constipation (n = 4, 44.4%), and fatigue (n = 4, 44.4%). Locoregional tumor control was obtained in all nine patients (100%) (mean observation time, 157 days). Complete clinical response was seen in three patients (33.3%), partial response was seen in three patients (33.3%), minor response was seen in one patient (11.1%), and two patients (22.2%) had stable disease. Median time to local progression of disease has not been reached (range, 35-356 days).
ONYX-015 adenovirus plus systemic cisplatin and 5-fluorouracil provides antitumor activity and local tumor control in patients with recurrent squamous cell carcinoma of the head and neck. This novel treatment approach offers hope for patients with limited treatment alternatives and provides the foundation for a phase III clinical trial.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>11005557</pmid><doi>10.1007/BF02725338</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2000-09, Vol.7 (8), p.588-592 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19606723 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adenovirus Adenoviruses, Human - genetics Aged Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - therapy Cisplatin - adverse effects Cisplatin - therapeutic use Disease Progression Female Fluorouracil - adverse effects Fluorouracil - therapeutic use Gene Deletion Genetic Therapy - methods Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - therapy Humans Injections Male Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - therapy Remission Induction |
| title | A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A23%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective%20phase%20II%20trial%20of%20ONYX-015%20adenovirus%20and%20chemotherapy%20in%20recurrent%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20(the%20Baylor%20experience)&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Lamont,%20J%20P&rft.date=2000-09&rft.volume=7&rft.issue=8&rft.spage=588&rft.epage=592&rft.pages=588-592&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1007/BF02725338&rft_dat=%3Cproquest_cross%3E1571790581%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227341940&rft_id=info:pmid/11005557&rfr_iscdi=true |